Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives

摘要

A timeline for FDA-approved products for chemotherapy, immunotherapy and chemoimmunotherapy from 2015 to 2020. SCLC small cell lung cancer, NSCLC non-small cell lung cancer, LMS leiomyosarcoma, LPS liposarcoma, CRC colorectal cancer, NET neuroendocrine tumors, MCC merkel cell carcinoma, AML acute myeloid leukemia, cSCC cutaneous squamous cell carcinoma, NSq NSCLC non-squamous non-small cell lung cancer, sALCL systemic anaplastic large cell lymphoma, PTCL peripheral T cell lymphomas, CHL classical hodgkin lymphoma, ES-SCLC extensive-stage small cell lung cancer, TNBC triple-negative breast cancer, DLBCL diffuse large B cell lymphoma, LG-UTUC low-grade upper tract urothelial cancer